FDA warns against purchasing and using counterfeit Albutein medicine

The Food and Drug Administration (FDA) has issued a statement urging the public not to purchase or use counterfeit medicines that closely resemble Albutein, which has received drug registration in Myanmar, as they have been found to be distributed and sold in the market. The FDA stated that it is continuously monitoring and supervising the market to ensure that the public can use high-quality, effective, and safe medicines. The statement indicated that the identified counterfeit medicine is an Albutein 20% Solution for IV Infusion with IP specifications, which closely resembles the US-made Albutein 20% Solution for IV Infusion [Albumin (Human) USP 20g/100 mL] that has received drug registration in Myanmar. Therefore, the public is urged not to purchase or use the counterfeit Albutein 20% Solution for IV Infusion with IP specifications, and to only purchase and use medicines that bear the Myanmar drug registration number. Albutein 20% Solution for IV Infusion is a type of intravenous infusion that replenishes albumin protein in human blood plasma, and it is a medicine that must be administered intravenously under the supervision of a doctor or healthcare professional in emergency and critical medical conditions.